Cancer — Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
Citation(s)
A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects